(Total Views: 535)
Posted On: 03/30/2021 12:36:02 PM
Post# of 148936
Re: Goosebumps #84767
Not really...
perhaps 60% less... not 100%!
"The group attribute around half of these cases to sources other than the coinhabiting healthcare worker, based on previous estimates, and thus the true drop in transmission is estimated to be around 60% having received a single dose of the vaccine. "
https://www.news-medical.net/news/20210323/CO...study.aspx
"Vaccinated People Can Get Covid, but It’s Most Likely Very Rare"
https://www.nytimes.com/2021/03/23/health/cov...eople.html
"B.1.1.7 variant
In December 2020, a new SARS‑CoV‑2 variant, B.1.1.7, was identified in the UK.[154] Early results suggest protection to the UK variant from the Pfizer and Moderna vaccines.[155][156] One study indicated that the Oxford–AstraZeneca vaccine had an efficacy of 42–89% against the B.1.1.7 variant, versus 71–91% against non-B.1.1.7 variants.[157] Preliminary data from a clinical trial indicated that the Novavax vaccine was ~96% effective for symptoms against the original variant, ~86% against B.1.1.7, and ~60% against the "South African" B.1.351 variant.[158]
501.V2 variant
Moderna has launched a trial of a vaccine to tackle the South African 501.V2 variant (also known as B.1.351).[159] On 17 February 2021, Pfizer announced neutralization activity was reduced by two-thirds for the 501.V2 variant, while stating no claims about the efficacy of the vaccine in preventing illness for this variant could yet be made.[160] Decreased neutralizing activity of sera from patients vaccinated with Moderna and Pfizer vaccines against B.1.351 was latter confirmed by several studies.[156][161]
In January, Johnson & Johnson, which held trials for its Ad26.COV2.S vaccine in South Africa, reported the level of protection against moderate to severe COVID-19 infection was 72% in the United States and 57% in South Africa.[162]
On 6 February 2021, the Financial Times reported that provisional trial data from a study undertaken by South Africa's University of the Witwatersrand in conjunction with Oxford University demonstrated reduced efficacy of the Oxford–AstraZeneca COVID-19 vaccine against the 501.V2 variant.[163] The study found that in a sample size of 2,000 the AZD1222 vaccine afforded only "minimal protection" in all but the most severe cases of COVID-19.[164] On 7 February 2021, the Minister for Health for South Africa suspended the planned deployment of around 1 million doses of the vaccine whilst they examine the data and await advice on how to proceed.[165][166]
P1 variant
The P1 variant (also known as 20J/501Y.V3), initially identified in Brazil, seems to partially escape vaccination with the Pfizer/BioNtech vaccine.[161]
https://en.wikipedia.org/wiki/COVID-19_vaccine
"Covid-Mutationen könnten Impfstoffe in nur einem Jahr unwirksam machen"
https://www.lifepr.de/inaktiv/oxfam-deutschla...xid/841485
Also interesting:
https://www.aerzteblatt.de/nachrichten/122558...che-Organe
perhaps 60% less... not 100%!
"The group attribute around half of these cases to sources other than the coinhabiting healthcare worker, based on previous estimates, and thus the true drop in transmission is estimated to be around 60% having received a single dose of the vaccine. "
https://www.news-medical.net/news/20210323/CO...study.aspx
"Vaccinated People Can Get Covid, but It’s Most Likely Very Rare"
https://www.nytimes.com/2021/03/23/health/cov...eople.html
"B.1.1.7 variant
In December 2020, a new SARS‑CoV‑2 variant, B.1.1.7, was identified in the UK.[154] Early results suggest protection to the UK variant from the Pfizer and Moderna vaccines.[155][156] One study indicated that the Oxford–AstraZeneca vaccine had an efficacy of 42–89% against the B.1.1.7 variant, versus 71–91% against non-B.1.1.7 variants.[157] Preliminary data from a clinical trial indicated that the Novavax vaccine was ~96% effective for symptoms against the original variant, ~86% against B.1.1.7, and ~60% against the "South African" B.1.351 variant.[158]
501.V2 variant
Moderna has launched a trial of a vaccine to tackle the South African 501.V2 variant (also known as B.1.351).[159] On 17 February 2021, Pfizer announced neutralization activity was reduced by two-thirds for the 501.V2 variant, while stating no claims about the efficacy of the vaccine in preventing illness for this variant could yet be made.[160] Decreased neutralizing activity of sera from patients vaccinated with Moderna and Pfizer vaccines against B.1.351 was latter confirmed by several studies.[156][161]
In January, Johnson & Johnson, which held trials for its Ad26.COV2.S vaccine in South Africa, reported the level of protection against moderate to severe COVID-19 infection was 72% in the United States and 57% in South Africa.[162]
On 6 February 2021, the Financial Times reported that provisional trial data from a study undertaken by South Africa's University of the Witwatersrand in conjunction with Oxford University demonstrated reduced efficacy of the Oxford–AstraZeneca COVID-19 vaccine against the 501.V2 variant.[163] The study found that in a sample size of 2,000 the AZD1222 vaccine afforded only "minimal protection" in all but the most severe cases of COVID-19.[164] On 7 February 2021, the Minister for Health for South Africa suspended the planned deployment of around 1 million doses of the vaccine whilst they examine the data and await advice on how to proceed.[165][166]
P1 variant
The P1 variant (also known as 20J/501Y.V3), initially identified in Brazil, seems to partially escape vaccination with the Pfizer/BioNtech vaccine.[161]
https://en.wikipedia.org/wiki/COVID-19_vaccine
"Covid-Mutationen könnten Impfstoffe in nur einem Jahr unwirksam machen"
https://www.lifepr.de/inaktiv/oxfam-deutschla...xid/841485
Also interesting:
https://www.aerzteblatt.de/nachrichten/122558...che-Organe
(4)
(0)Scroll down for more posts ▼
